Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Marino Martinez Vargas

Internal Medicine Tallahassee, FL Medical Doctor

NPI 1750680856 CMS profile 260772

4012 Kelcey Ct Ste 203, Tallahassee, FL 32308

Open in the dashboard

General payments

$6,851

385 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marino Martinez Vargas of Tallahassee, FL is reported in the CMS Open Payments database as having received $6,851 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,046 55
2024 General $1,672 85
2023 General $1,183 73
2022 General $1,856 105
2021 General $829 56
2020 General $264 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marino Martinez Vargas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Marino Martinez Vargas were reported at $1,046. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Marino Martinez Vargas Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $264 $119 $33–$402 $114
2021 $829 $135 $37–$521 $132
2022 $1,856 $141 $42–$496 $149
2023 $1,183 $149 $45–$519 $160
2024 $1,672 $154 $47–$537 $164
2025 $1,046 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $1,177 72 payments
  2. AbbVie, Inc. $756 55 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $683 38 payments
  4. AstraZeneca Pharmaceuticals LP $662 35 payments
  5. Pfizer Inc. $429 24 payments
  6. Novartis Pharmaceuticals Corporation $418 24 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $383 17 payments
  8. Lilly USA, LLC $328 24 payments
  9. PhotoniCare Inc $297 2 payments
  10. Merck Sharp & Dohme Corporation $227 10 payments
  11. Other $1,492 84 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $6,572 384 payments
  2. Debt forgiveness $278 1 payment
Products named General payments · program years 2020–2025
  1. RYBELSUS $1,026 61 payments
  2. Ozempic $903 61 payments
  3. Kerendia $683 38 payments
  4. FARXIGA $494 28 payments
  5. NURTEC ODT $384 22 payments
  6. VRAYLAR $330 25 payments
  7. OtoSight Middle Ear Scope $297 2 payments
  8. ENTRESTO $278 18 payments
  9. VERQUVO $241 11 payments
  10. ZAVZPRET $240 14 payments
  11. Other $4,330 252 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 133 drugs

Part D claims

6,773

Median for Internal Medicine: 777

Drug cost

$1,060,214

Median for Internal Medicine: $73,373

Branded share of claims

21.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 172 $190,163
Eliquis Apixaban Brand 146 $143,647
Farxiga Dapagliflozin Propanediol Brand 73 $94,646
Januvia Sitagliptin Phosphate Brand 67 $78,455
Jardiance Empagliflozin Brand 63 $75,414
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $56,643
Xarelto Rivaroxaban Brand 38 $46,875
Ozempic Semaglutide Brand 41 $46,733
Entresto Sacubitril/Valsartan Brand 17 $35,416
Budesonide Er Budesonide Brand 12 $28,300

The 10 drugs with the highest cost, of 133 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$78,427

Of which drugs: $535

Medicare patients

219

Average age 74

Services billed

1,464

116 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 37%
Arthritis 37%
Ischemic heart disease 31%
Chronic kidney disease 28%
Heart failure 21%
Depression 21%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 21 21 $460

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $213
$213 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $120
$120 63 —
VRAYLAR
  • AbbVie, Inc. $96
$96 11 —
RYBELSUS
  • Novo Nordisk Inc $80
$80 — —
Ozempic
  • Novo Nordisk Inc $80
$80 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record